2024
Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
Riva E, Calvi M, Zampini M, Dall'Olio L, Merlotti A, Russo A, Maggioni G, Orlandi L, Frigo A, Ficara F, Crisafulli L, Sauta E, D'Amico S, Lugli E, Campagna A, Ubezio M, Tentori C, Todisco G, Lanino L, Buizza A, Ventura D, Pinocchio N, Saba E, Santoro A, Santini V, van de Loosdrecht A, Komrokji R, Garcia-Manero G, Fenaux P, Ades L, Platzbecker U, Haferlach T, Almeida A, Zeidan A, Kordasti S, Remondini D, Castellani G, Di Vito C, Mavilio D, Della Porta M. Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium. Blood 2024, 144: 665-665. DOI: 10.1182/blood-2024-200184.Peer-Reviewed Original ResearchMyelodysplastic syndromeImmune dysfunctionClinical work-upIPSS-MHypomethylating agentsBone marrowImmune ecosystemNatural killerNK cellsImmune monitoringPeripheral bloodT cellsAntibody panelClinical heterogeneity of myelodysplastic syndromesPatients treated with hypomethylating agentsCohort of MDS patientsLevel of immune dysfunctionRisk of leukemic transformationResponse to hypomethylating agentsHeterogeneity of myelodysplastic syndromesMulti-color flow cytometryWork-up of patientsClinical work-up of patientsImmune monitoring approachesMDS microenvironment
2023
Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study
Santini V, Zeidan A, Fenaux P, Madanat Y, Berry T, Feller F, Sun L, Xia Q, Wan Y, Huang F, Savona M, Platzbecker U. Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study. Blood 2023, 142: 4603. DOI: 10.1182/blood-2023-179378.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesPlacebo groupTransfusion independenceTI ratesHot spot mutationsPoor prognosisMyelodysplastic syndromeRed blood cell transfusion independenceASXL1 mutationsErythropoiesis-stimulating agentsPhase 3 studyStudy of patientsTI responsesPresence of mutationsSpecific mutationsClinical responseStudy entryClinical efficacyClinical benefitPeripheral bloodMutation subgroupsDNMT3A mutationsEpigenetic modifiersPatientsRUNX1 mutations
2021
Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Bewersdorf J, Hasle V, Thompson E, de Menezes D, Rose S, Boss I, Fox B. Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2021, 138: 3371. DOI: 10.1182/blood-2021-146329.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeClinical Trials CommitteeAcute myeloid leukemiaBristol-Myers SquibbCurrent equity holderPoor-risk cytogeneticsVariant allele frequencyAML ptsOverall response rateTrials CommitteeMedian OSTP53 mutationsMyeloid neoplasmsFlow cytometryPeripheral bloodT cell genesHigh expressionBone marrowAverage variant allele frequencyRandomized phase 2 studyBone marrow flow cytometryT-cell gene signatureTumor cellsBM blast percentageIPSS-R score